- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773 low dose, Placebo BI 10773 high dose, BI 10773 high dose, Placebo BI 10773 low dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,064 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 170
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 140 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo identical to BI 10773 high dose, Placebo identical to BI 10773 low dose, BI 10773
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Huntington Park, California + 21 more
- Conditions
- Diabetes Mellitus, Type 2, Renal Insufficiency
- Interventions
- BI 10773, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 741 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 18
- States / cities
- Anaheim, California • Lomita, California • Plantation, Florida + 15 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 27
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more